Forian Inc. has announced its financial results for the second quarter of 2025, demonstrating significant growth and operational efficiency. The company reported a revenue of $7.5 million, marking a 56% increase from the $4.8 million recorded in the same period last year. This growth is attributed to strategic contract renewals, new client acquisitions, and the expansion of core capabilities.
Net income for the quarter stood at $0.2 million, or $0.01 per share, a substantial improvement from a net loss of $2.6 million, or $0.08 per share, in the prior year. Adjusted EBITDA also saw a dramatic increase to $0.6 million, compared to $0.1 million in the previous year, underscoring the company's enhanced profitability and margin expansion. Forian's cash, cash equivalents, and marketable securities totaled $35.6 million as of June 30, 2025, providing a solid foundation for future investments and growth.
Max Wygod, CEO and Executive Chairman of Forian, emphasized the company's commitment to both organic growth and strategic investments to strengthen its platform and deliver value across the healthcare ecosystem. The company has also reconfirmed its full-year 2025 outlook, expecting revenue to be between $28 to $30 million and Adjusted EBITDA to range from ($1.0) to $1.0 million.
Forian's performance in the second quarter of 2025 reflects its ability to leverage data science and analytics to drive operational and financial improvements. The company's focus on developing its business, expanding its capabilities, and generating positive momentum in its markets has positioned it as a key player in the healthcare and life sciences industries. For more information on Forian's financial results and to listen to the conference call discussing these results, visit https://www.forian.com/investors.
